Central Line Catheters Market

Central Line Catheters Market Outlook (2023 to 2033)

In 2023, the global central line catheters market is expected to generate US$ 2.7 billion in revenue. The market is predicted to expand at 6.6% CAGR and reach a size of US$ 5.1 billion by the end of 2033.

Central line catheters are flexible, thin tubes used across healthcare units such as hemodialysis units and critical care or oncology departments. They are an essential part of various applications, including rapid fluid resuscitation, drug administration, parenteral nutrition, and hemodialysis. They come in various sizes, types, and sites, and can sometimes cause complications. Central line catheter kits, including catheters in triple-lumen, double-lumen, and large bore single-lumen, are crucial for improving critically ill patients. They are used for delivering multiple medications, continuous infusion chemotherapy, parenteral nutrition, and vesicant drugs.

• Peripherally inserted central catheters (PICCs) occupied a market share of 37.8% in 2022.
• Revenue from the sales of central line catheters accounted for 4.9% share of the global catheters market in 2022.

The central line is preferred for vesicant drug administration due to its larger bores and heparin requirements. The femoral vein is avoided due to a higher rate of infection and thrombosis compared to the subclavian vein, which has a lower infection rate.

Central line catheters can be non-tunneled for easy insertion in emergent situations, including emergency or temporary hemodialysis, cardiac catheterization, vascular access in unstable patients, transvenous pacemaker placement, and large-volume fluid administration. Non-emergent indications include total parental nutrition and frequent routine blood draws, which require hypertonic saline solutions, large amounts of potassium, or calcium chloride.

• As per a research article published in Frontiers - Medicine 2022, central line catheterization is a common procedure performed on approximately 8% of all hospitalized patients.

Central line catheter installation is required for a variety of reasons, including medication delivery, extended intravenous therapy, problematic peripheral venous access, monitoring, and specific treatment. Patients who require central line catheterization during hospital stays must get proper care, which includes routine insertion checks, daily monitoring, and adherence to clinical governance requirements. Monitoring ensures that central venous pressure, oxygen saturation, and fluid resuscitation are maintained.

How are Central Line Catheters Beneficial for Manufacturers as Well as Healthcare Providers?

“Rising Prevalence of Chronic Illnesses and Development of Antimicrobial Catheters”

Central line catheters are commonly used in the management of chronic diseases, such as cancer, kidney failure, and cardiovascular disorders. The growing prevalence of these conditions contributes to the increased demand for central line catheters. The trend of hospital acquisitions has resulted in larger healthcare systems and high patient volume. This consolidation creates economies of scale, allowing hospitals to negotiate better pricing and volume discounts for medical devices, including central line catheters.

• A study by BMC Anesthesiology 2019, comparing ultrasound-guided and direct central venous catheterization found ultrasound-guided catheterization more successful and less expensive.

Dual-lumen catheters provide continuous venovenous hemofiltration without affecting thrombogenicity, flow resistance, or hemodynamics. Training for multidisciplinary teams is critical for the success of any procedure, and periodic bundle monitoring assists in uncovering weaknesses and giving feedback to enhance patient care quality.

Millions of catheters are implanted annually in health services for managing acute and chronic diseases in adults and pediatric patients. Central venous access is performed using central venous catheters (CVCs) or peripherally inserted central catheters (PICCs), with various types available depending on the time required. PICCs are recommended for short- and medium-term use.

Routine central venous catheter treatment is critical for lowering catheter-related infections and consequences such as abscesses, cellulitis, and bacteremia. To avoid difficulties and guarantee correct handling and care of the central catheter, healthcare staff must undertake periodic maintenance and troubleshooting.

Several manufacturers are introducing innovative product lines like antimicrobial-coated catheters in the market to gain a competitive edge. These catheters help inhibit the growth of bacteria, preventing colonization and subsequent infection due to the incorporation of antimicrobial agents, such as silver, chlorhexidine, or minocycline, into the catheter surface. Such products have the potential to reduce the risk of catheter-related bloodstream infections (CRBSIs) significantly.

What are the Barriers to the Adoption of Central Line Catheters?

“Device Dysfunction and Complications Associated with Central Line Catheters Leading to Patient Safety Concerns”

The complication rate of central line insertions is a significant concern, with errors made during the procedure causing complications. Ultrasound guidance has been shown to decrease the risk of complications at all central line access sites. Cardiac complications, such as catheter and wire entanglement with inferior vena cava (IVC) filters and arrhythmias have been reported. Infection and device dysfunction are a few delayed complications of central line insertion, which can occur in weeks to months.

• Central line-associated infections can lead to shock, sepsis, and even death, with an incidence of 80 to 189 episodes in every 100,000 patient years as per a Cureus 2019 article.

Device dysfunction is a significant restraint on market growth. Malfunctions or failures of central line catheter devices can have serious implications for patient safety and treatment outcomes. Device dysfunction can lead to complications such as infections, blockages, or improper fluid or medication administration. These incidents erode patient trust and can result in legal consequences for manufacturers. As a result, regulatory bodies impose stringent quality and safety standards, increasing compliance requirements and costs for manufacturers.

Product recalls are another hindrance that impacts market growth as it leads to manufacturers absorbing the product replacement cost, reimbursement cost, and legal cost among many others, ultimately leading to multi-billion dollars in losses.

• In June 2023, the FDA issued a Class I recall of over 260,000 Teleflex catheter systems due to concerns about catheter separation and leakage, potentially causing injury or death.

Device dysfunction also poses a risk to healthcare providers, who may face operational disruptions and increased healthcare costs. Addressing and minimizing device dysfunction is crucial to ensuring market growth and maintaining patient safety in the central line catheters market. Addressing these errors and managing complications is crucial to reducing the occurrence of complications in central line use.

Country-wise Insights

Why is the United States a Profitable Market for Central Line Catheter Manufacturers?

“Increasing Demand for Central Line Catheters in Hospital Settings Driven by Rising Cancer and Infectious Disease Cases”

The United States accounted for 39.7% share of the global central line catheters market in 2022.

Central line catheterization is a yearly practice performed in hospital settings for intravenous fluids, blood transfusions, and chemotherapy.

• According to the 2023 National Institute of Health research article, over 5 million catheters are inserted yearly in both hospitalized as well as surgical patients in the United States.
• As per CA: A Cancer Journal for Clinicians 2022, the National Center for Health Statistics predicted 1,918,030 new cancer cases and 609,360 deaths in 2022, with lung cancer being the leading cause of death.
• As per the American Hospital Association 2023, more than 34 million admissions took place in hospitals in the United States in 2022.

Rising cases of cancer along with other infectious diseases in the United States are likely to increase the number of hospital admissions. This, in turn, is foreseen to generate demand for central line catheters across healthcare facilities, providing lucrative growth opportunities for market players.

How is the Market in China Shaping Up?

“Growing Adoption of Cancer Therapeutics and Active Participation from Healthcare Services”

China accounted for 6.3% share of the global market in 2022.

A PICC is a reliable intravenous access method with high patient satisfaction.

• The Chinese Nursing Association's expert consensus on venous catheter maintenance recommends aseptic technique maintenance at least once a week, including function evaluation, infusion connectors, dressing replacement, flushing, sealing, and health education.

Leukemia is a common malignant disease in China that is treated with chemotherapy, with PICCs being a primary route. This boosts the demand for catheters in China.

Which Factors Contribute to Increased Demand for Central Line Catheters in Germany?

“Widespread Use of Advanced Ultrasound Guidance for Central Line Catheterization”

The market in Germany accounted for 4.8% share of the global market in 2022.

Germany has implemented advanced ultrasound guidance (UG) for catheterization using central line catheters, with sonographic techniques like Doppler and two-dimensional ultrasound being used more commonly.

• UG is considered a cost-saving catheterization strategy, with over a half million catheters placed annually according to The Federal Statistics Office (Destatis). Health: DRG-Statistics, 2016. A study also found that UG is more successful in avoiding surgery-related problems and less expensive than landmark-focused catheterization, potentially saving €10.2 million per year for the German Statutory Health Insurance (SHI).

Category-wise Insights

Why PICCs are Extensively Utilized Worldwide?

“PICC’s Role in Maintaining Vascular System Integrity and Effectively Delivering Antibiotics and Chemotherapy Medications”

PICCs occupied 37.8% share of the global market in 2022.

A PICC is a thin, flexible tube used to give antibiotics or chemotherapy medications intravenously while maintaining the integrity of the peripheral vascular system. PICCs are used in both intensive care units and regular medical wards.

Central line catheter insertion is essential for emergent and non-emergent indications, such as transvenous pacemaker placement, cardiac output measurement, large-volume fluid administration, and administration of medications.

Which Design Accounts for High Revenue Generation?

“Enhanced Vascular Access Offered by Double Lumen Catheters for Continuous Venovenous Hemofiltration”

By design, the double-lumen segment accounted for 63.2% share of the global market in 2022.

Dual-lumen catheters are designed for vascular access in dialysis patients, providing continuous venovenous hemofiltration without affecting thrombogenicity, flow resistance, or hemodynamics. Catheters are typically dual-lumen devices that incorporate both access and return limbs in one device. Single-lumen catheters require two, while triple-lumen catheters have a third narrow lumen for other purposes.

Early dual-lumen catheters had a coaxial design, with blood removed through an outer cannula and returned through a narrow inner cannula. Modern catheters have parallel lumens, reducing the risk of recirculation and improving efficiency. Dual-lumen catheters have many side holes for flexibility and help in quick hemodialysis with minimal complications.

Why Do Non-Antimicrobial Catheters Account for Bulk of Overall Sales?

“Cost-Effectiveness and Reduced Antibiotic Resistance Concerns with Non-Antimicrobial Lock Solutions in Home Parenteral Nutrition”

Non-antimicrobial catheters held 75.9% share of the global market in 2022.

The cost of antimicrobial central line catheters is comparatively higher than non-antimicrobial catheters, which increases hospital charges.

Patients on home parenteral nutrition (HPN) are in constant need of central venous access for long-term sustenance, and catheter-associated bloodstream infections (CRBSIs) in such patients is a significant threat. Lock solutions with antibiotics like vancomycin are commonly used in antimicrobial catheters to decrease catheter-related infections. These lock solutions were traditionally composed of antibiotics, but their use to treat infections was restricted due to concerns regarding antibiotic-resistant microorganisms.

Non-antimicrobial catheters with lock solutions like taurolidine, ethanol, citrate, and tetrasodium EDTA are now preferred over antimicrobial central line catheters.

Why are Polyurethane Central Line Catheters Preferred over Other Compositions?

“Increased Durability and Geometrical Consistency of Polyurethane Central Line Catheters Fueling Their Sales”

By composition, polyurethane catheters accounted for 64.6% share of the global market in 2022.

Total implanted venous access devices (TIVADs) are central line catheters that are utilized in cancer patients on a long-term basis. They are made up of silicone or polyurethane catheters that are linked to a subcutaneous reservoir. Polyurethane catheters offer higher geometrical consistency and less granularity inside walls than silicone dual-lumen catheters, resulting in fewer fractures.

Which End User Accounts for Most Utilization of Central Line Catheters?

“Hospitals Facilitating Quick ICU Access with Experienced Surgeons”

By end user, hospitals accounted for 58.2% share of the global market in 2022.

To provide long-term access to central line catheters in hospitals, a specialized team of surgeons, nurses, and pharmacists is required. However, since more patients are being treated outside of the ICU, PICCs are becoming increasingly prevalent.

PICC lines can be placed at the bedside with ultrasound guidance by trained nursing personnel, allowing for rapid central line access in ICUs and regular medical wards. In many hospitals, anesthesiologists, surgeons, emergency department physicians, radiologists, and critical care physicians can introduce central lines. All these factors increase the preference for hospitals among patients.

Competition Landscape

The central line catheters industry is highly fragmented, with several competitors offering products and services locally. These businesses are using strategies such as enhanced research and development and expansions to meet patients’ demands and grow their customer base.

• In June 2023, Teleflex introduced Triumph™ Catheter and GuideLiner® Coast™ Catheter, FDA-approved catheter devices for complex percutaneous coronary interventions, enhancing deliverability and backup support in Teleflex's guide expansion portfolio.
• In April 2023, Becton, Dickinson launched the BD Prevue II System, an advanced ultrasound device with a specialized probe for optimal IV placement, reducing vascular access procedures and improving safety for clinicians and patients.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies manufacturing central line catheters, which are available in the full report.

Central Line Catheters Industry Report Scope

Key Segments of Central Line Catheters Industry Research

Product:

• Peripherally Inserted Central Catheters (PICCs)
• Implanted Ports
• Tunneled Central Venous Catheters
• Non-tunneled Central Venous Catheters

Design:

• Single Lumen
• Double Lumen
• Multiple Lumen

Property:

• Antimicrobial Catheters
• Non-antimicrobial Catheters

Composition:

• Polyurethane
• Teflon
• Silicone Rubber

End User:

• Hospitals
• Ambulatory Surgical Centers
• Specialized Clinics
• Cancer Research Institutes

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

To know more about delivery timeline for this report Contact Sales